Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
117 studies found for:    coronado
Show Display Options
Rank Status Study
1 Withdrawn TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Unknown  Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
3 Unknown  Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
4 Terminated Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
5 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
6 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Active, not recruiting A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Conditions: Hepatitis C Viral Infection;   Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 4
Interventions: Drug: Faldaprevir;   Drug: TD-6450;   Drug: Ribavirin
8 Active, not recruiting Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Conditions: Hepatitis C;   Cirrhosis
Interventions: Drug: daclatasvir;   Drug: Sofosbuvir, Sovaldi;   Drug: Ribavirin
9 Completed
Has Results
The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin
Condition: Epilepsy
Interventions: Drug: BIA 2-093;   Drug: Placebo;   Drug: Digoxin
10 Completed
Has Results
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
Condition: Neuropathic Pain
Interventions: Drug: Metformin;   Drug: Eslicarbazepine acetate
11 Completed Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin
Condition: Healthy
Interventions: Drug: BIA 3-202;   Drug: warfarin
12 Completed Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
Condition: Parkinson's Disease (PD)
Interventions: Drug: BIA 3-202;   Drug: Placebo;   Drug: levodopa 100 mg / benserazide 25 mg
13 Completed Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
Condition: Epilepsy
Interventions: Drug: BIA 2-093;   Drug: Gliclazide
14 Completed Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
Condition: Parkinson's Disease
Interventions: Drug: BIA 3-202;   Drug: Placebo;   Drug: Sinemet®
15 Completed Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
Condition: Parkinson's Disease
Interventions: Drug: Nebicapone;   Drug: Placebo
16 Completed Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
Condition: Parkinson's Disease
Interventions: Drug: BIA 3-202;   Drug: Placebo;   Drug: Madopar® 125
17 Completed Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)
Condition: Parkinson's Disease
Interventions: Drug: BIA 3-202;   Drug: Placebo;   Drug: Sinemet 25/100
18 Completed
Has Results
Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.
Condition: Epilepsy
Interventions: Drug: BIA 2-093;   Drug: Contraceptives, Oral, Combined
19 Completed
Has Results
The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093
Condition: Epilepsy
Intervention: Drug: BIA 2-093
20 Completed
Has Results
A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093
Condition: Epilepsy
Interventions: Drug: BIA 2-093;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.